focus -WSS

focus

author：explore 2025-09-04 04:26:03 - browse：3

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Senators start work on Medicare physician payment reform

explore

WSS

Key House Republican on health care plans exit from Congress

Medicare Advantage proposed rates disappoint insurers

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

ALS groups 'won't be played again' by the FDA, drug sponsors

Vaccine advisory panel ACIP left half staffed by HHS

FogPharma raises $145 million in rare Series E round

Wikipedia

focus

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

How digital tools helped lower hypertension in marginalized patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to fix the rural physician shortage in the U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

BioAge raises $170M for combination therapy with Zepbound

Novavax promises a turnaround & Lilly roils the obesity market

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Biden report: The neurospychology of memory and aging

Kenai launches with $82 million for Parkinson’s stem cell therapy

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Biogen Alzheimer’s drug launch off to slow start

Flu vaccine offering decent levels of protection this winter, new data show

knowledge

explore

hotspot

knowledge